BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • BCI
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Wednesday, July 29, 2026
Home » Blogs » BioWorld MedTech Perspectives » Precision Skepticism

BioWorld MedTech Perspectives
BioWorld MedTech Perspectives RSS FeedRSS

Medical technology

Precision Skepticism

March 30, 2015
By Mark McCarty

Eppur si muove, indeed, but to what effect?
Eppur si muove, indeed, but to what effect?

From time to time, it's nice to rediscover I'm not the only cynic in the room. So I was obviously relieved to see a couple of criticisms of the latest orthodoxy about the future practice of medicine. The question is: Is the Precision Medicine Initiative the real deal or just another government gamble on the ponies?

Goldilocks syndrome

Rita Rubin writes in the March 17 issue of the Journal of the American Medical Association that the hyperbole surrounding the President's Precision Medicine Initiative (or PMI) has raised a few eyebrows, albeit for different reasons. Rubin cites Jeffrey Matthews, chair of the department of surgery at the University of Chicago, as arguing that the title of the program exceeds the program's likely reach.

Matthews is said to have stated that precision medicine sounds great on paper, but "it is being oversold and overhyped, and it's creating unrealistic expectations on the part of patients and clinicians." Of course PMI is far from alone in this, as the much-ballyhooed Critical Path Initiative and the parallel review program run by FDA and CMS make clear.

Big data maven Eric Topol of the Scripps Translational Science Institute is credited with a skepticism of a different brand. Rubin quotes Topol as saying, "the science is catapulting forward" toward precision medicine, but that genetic sequencing fills in only one layer of the picture.

"If you really want to change medicine, you have to have all the information on the individual," Topol stated, making the argument that even information on the bacterial environment in the gut is necessary to leverage this new medical paradigm. Topol may be right, but one has to ask whether it's even remotely plausible to economically come up with that much information.

Not to take a shot at Topol, but sooner or later, someone will ask whether the relationship between the individual and his or her parents is essential to a true personalized/precision medicine paradigm. That's how we'll know for certain that all this emphasis on precision has gone too far.

The past as epilogue

Another point of consideration is that the PMI calls for the collection of data on a million Americans and the use of smart phones and so on to evaluate the interaction between genes and other factors, such as environmental factors.

We might note that government finally (and mercifully) pulled the plug on the National Children's Study and that bisphenol A has been pretty much exonerated from any culpability where human disease is concerned. The National Children's Study suffered from no shortage of ambition or of bogeymen, and we might ask ourselves if the Precision Medicine Initiative, relying as it will on electronic health record interoperability, is likely to meet the same fate, especially given that lifestyle is still a big – maybe the biggest – factor in declining health.

Time will tell, but I'd point out that betting against government's blind ambitions does not routinely result in a bad day at the horse track.

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 29, 2026.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for July 28, 2026
  • Illustration of dopamine signaling in the brain

    New schizophrenia targets challenge trial design

    BioWorld
    The search for better schizophrenia therapies is moving beyond dopamine toward a growing number of experimental targets. According to researchers, the repeated...
  • Regulatory actions for July 27, 2026

    BioWorld
    Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Alfasigma,...
  • Other news to note for July 27, 2026

    BioWorld
    Biopharma and med-tech happenings, including deals and partnerships, and other news in brief: Abbvie, Genmab, Merck, Par, Thyora.
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
    • Videos
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing